These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 14383431)

  • 21. [Azotemic nephritis during antimony therapy of a case of infantile visceral leishmaniasis].
    CHARLAS R; BENABADJI A
    Maroc Med; 1962 Dec; 41():1180-2. PubMed ID: 14020224
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pluri-focal cutaneous leishmaniasis treated with intralesional glucantime].
    Duperrat B; Puissant A; Fischer R; Badillet G; Mascaro JM
    Bull Soc Fr Dermatol Syphiligr; 1966; 73(2):219-20. PubMed ID: 5914173
    [No Abstract]   [Full Text] [Related]  

  • 23. [Leishmaniasis mucocutaneous americana; our experience in its treatment with glucantime].
    CORNEJO A
    Prensa Med Argent; 1955 Jun; 42(22):1605-6. PubMed ID: 13254644
    [No Abstract]   [Full Text] [Related]  

  • 24. Activity of antimony dextran glycoside (RL-712) against visceral leishmaniasis in the hamster.
    Mikhail JW; Khayyal MT; Girgis NI
    Bull World Health Organ; 1969; 40(2):327-8. PubMed ID: 5306550
    [No Abstract]   [Full Text] [Related]  

  • 25. [Syndromes of reduced susceptibility to antimony in visceral leishmaniasis in the child].
    BOIX BARRIOS J; SANCHO PASQUAU V
    Rev Esp Pediatr; 1953; 9(49):41-53. PubMed ID: 13074963
    [No Abstract]   [Full Text] [Related]  

  • 26. Interleukin 10 receptor blockade--pentavalent antimony treatment in experimental visceral leishmaniasis.
    Murray HW
    Acta Trop; 2005 Mar; 93(3):295-301. PubMed ID: 15716043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apparent Glucantime failure in five patients with mucocutaneous leishmaniasis.
    Rocha RA; Sampaio RN; Guerra M; Magalhâes A; Cuba CC; Barreto AC; Marsden PD
    J Trop Med Hyg; 1980 Aug; 83(4):131-9. PubMed ID: 6997505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Behavior of antibodies (titrated by means of the immunofluorescence test) in visceral leishmaniasis treated by antimony therapy].
    Cascio G
    Pediatria (Napoli); 1970 Jul; 78(3):497-504. PubMed ID: 4920029
    [No Abstract]   [Full Text] [Related]  

  • 29. [Parenteral glucantime therapy of bouton d'orient, with esthetic results superior to intralesional therapy].
    NOGUER MORE S
    Actas Dermosifiliogr; 1952 May; 43(8):725-7. PubMed ID: 12976220
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antimony resistance in the treatment of visceral leishmaniasis].
    MIRZOIAN NA
    Med Parazitol (Mosk); 1957; 26(3):277-80. PubMed ID: 13482777
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of visceral leishmaniasis with solusurmin in children].
    KARAKHODZHAEV BKh
    Pediatriia; 1953; 4():60-1. PubMed ID: 13088230
    [No Abstract]   [Full Text] [Related]  

  • 32. [Association of acute lymphoblastic leukaemia and visceral leishmaniasis].
    Nafil H; Tazi I; Mahmal L
    Ann Biol Clin (Paris); 2011; 69(6):729-31. PubMed ID: 22123576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of cutaneous leishmaniasis with methylglucamine antimoniate (2.168 R. P.)].
    RAGU J; SCHNEIDER J
    Ann Dermatol Syphiligr (Paris); 1947 Feb; 7(2):38. PubMed ID: 20253292
    [No Abstract]   [Full Text] [Related]  

  • 34. [Case of sporotrichosis treated with N-methylglucamine antimoniate].
    BAPTISTA L; BELLIBONI N; CASTRO RM
    Rev Paul Med; 1952 Jul; 41(1):24-7. PubMed ID: 13014657
    [No Abstract]   [Full Text] [Related]  

  • 35. [Various clinical aspects of cutaneous leishmaniasis, a disease too often unrecognized in the Paris area. Diagnostic and therapeutic problems].
    Lapierre J; Piguet B; Tran-Vinh-Hien ; Chastanet B
    Sem Hop; 1975 Feb; 51(8):531-8. PubMed ID: 169586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Secretion of antimony and stilbamidine in the treatment of visceral leishmaniasis in children].
    MIKHAILOV VG
    Farmakol Toksikol; 1959; 22(2):175-8. PubMed ID: 13653152
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection.
    Hailu W; Weldegebreal T; Hurissa Z; Tafes H; Omollo R; Yifru S; Balasegaram M; Hailu A
    Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):706-12. PubMed ID: 20870258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine.
    Botelho AC; Mayrink W; Oliveira RC
    Acta Trop; 2009 Nov; 112(2):143-8. PubMed ID: 19631187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Two cases of infant kalaazar cure with N. methylglucamine antimoniate or 2.168-R. P].
    DIDIER R
    Arch Fr Pediatr; 1947; 4(1):82-6. PubMed ID: 20254679
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute phase proteins and plasma lipoproteins during antimony treatment in infantile visceral leishmaniasis.
    Kallel R; Bekaert ED; Dubois DY; Alcindor LG; Ayrault-Jarrier M; Mebazza A
    Clin Physiol Biochem; 1993; 10(1):8-12. PubMed ID: 8339522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.